Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (205)	4/10/1999 11:44:00 PM
From: scaram(o)uche	Respond to of 666

>> interim data from an ongoing Phase II clinical trial to evaluate the extent to which the therapeutic benefit of Bexxar is derived from the combination of the Anti-B1 Antibody and the radioisotope, in comparison to the Anti-B1 Antibody alone << I've been popping into this thread and others and asking about the cold antibody trial for a year. Now it's a part of the NDA submission? Fume. Thanks, Bob. From several directions, you're really bringing light to current status.